RespiFacile® a reusable, Hi-Tech nasal dilator to improve your breathing. Interventions include intranasal corticosteroids, decongestants and mechanical nasal dilators, and patient populations Noson Nasal Dilator have included subjects with clinical OSAS coexisting with rhinitis, upper airway resistance syndrome (UARS) patients and rhinitis patients without objective evidence of SDB.
The subject answered questions about the dry mouth feeling on a 1-5-scale (5 the driest) and answered a validated questionnaire about quality of sleep (Epworth Sleepiness Scale 53 ). These three instruments were administered immediately before and 2 weeks after the study started.



When choosing this type of anti-snoring device, there are a few things to pay attention to. The first is that each person's nostrils are of a different size and shape, which is why most products are available in multiple sizes, so it may be necessary to try out a few sizes to find the one which fits your nostrils best.
In fact, any internal nasal dilator without a positive retaining means, as disclosed herein, will fall out of the nose in practical use, according to extensive evaluation of the dilator of the present invention; in this event, the dilator would be inoperative, or at least not useful for the purpose intended.

A questionnaire was designed to evaluate the level of satisfaction with the given treatment and included questions regarding the impact of the treatment on sleep quality, feelings upon waking, difficulty falling asleep, and satisfaction with the treatment effect concerning daytime sleepiness.
In the subgroup with AHI 0-5, the nasal dilator was associated with a reduction in the number of spontaneous arousals during the night, which decreased from a mean (SD) of 7.74 (4.11) at baseline to 5.81 (3.74) at night 8 and 6.15 (4.16) at night 29 of the active phase (P value not determined) and from 10.50 (7.22) on the night without the strip to 8.37 (6.47) on the night with the strip in the nasal resistance phase (P = 0.0235).

On the ad hoc analysis, in the overall ITT population, the butterfly prototype and BRNS clear strips produced significantly (P < 0.05) greater improvement from baseline to day 7 than the placebo strip for PIRS nighttime sleep parameters (LS mean changes − 2.03, − 2.11, and − 1.05, respectively) and quality of life (− 2.68, − 3.12, and − 1.26, respectively).
Method: We carried out a multicentric prospective study of 15 patients, from November 2003 through June 2006, with patients using CPAP, divided into two groups: 10 with adhesion problems and five without adhesion problems, all examined for inclusion.

In a study carried out by Turnbull et al, 35 24 women between the 16th and 39th weeks of gestation with nasal congestion were randomized into two groups: one of them used placebo, and the other an END ( Table 4 ). The subjects were assessed during 3 nights.